AbbVie: third-quarter revenue in line and double-digit growth for several drugs
FROM THE WIRE · FINANCE.YAHOO.COM
AbbVie's third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Management highlighted the continued momentum of key products like SKYRIZI, RINVOQ, and VRAYLAR, each delivering double-digit…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly results in line with expectations, with a positive market reaction for the pharma group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revenue of $17.4 billion was in line with estimates.
- 02Adjusted EPS was $3.82 versus $3.77 expected.
- 03The CEO says nine key products delivered double-digit growth.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets